Journal article
Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis
Abstract
BACKGROUND: In Ontario, FOLFIRINOX (FFX) and gemcitabine + nab-paclitaxel (GnP) have been publicly funded for first-line unresectable locally advanced pancreatic cancer (uLAPC) or metastatic pancreatic cancer (mPC) since April 2015. We examined the real-world effectiveness and safety of FFX vs GnP for advanced pancreatic cancer, and in uLAPC and mPC.
METHODS: Patients receiving first-line FFX or GnP from April 2015 to March 2017 were identified …
Authors
Chan KKW; Guo H; Cheng S; Beca JM; Redmond‐Misner R; Isaranuwatchai W; Qiao L; Earle C; Berry SR; Biagi JJ
Journal
Cancer Medicine, Vol. 9, No. 1, pp. 160–169
Publisher
Wiley
Publication Date
1 2020
DOI
10.1002/cam4.2705
ISSN
2045-7634
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AgedAlbuminsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy-Induced Febrile NeutropeniaDeoxycytidineEmergency Service, HospitalFemaleFluorouracilFollow-Up StudiesHospitalizationHumansIrinotecanKaplan-Meier EstimateLeucovorinMaleMiddle AgedOntarioOxaliplatinPaclitaxelPancreatic NeoplasmsPropensity ScoreTreatment OutcomeGemcitabine